AstraZeneca's tozorakimab targets interleukin-33, a protein released by damaged cells that drives airway inflammation and mucus production in chronic obstructive pulmonary disease

From the articleAstraZeneca's COPD drug scores two late-stage trial wins as full data boosts blockbuster hopesAlso in Clinical trials show significant reduction in COPD flare-ups with investigational therapy, AstraZeneca drug reduces lung disease flare-ups in late-stage trials | Reuters, New drug shows promise in reducing COPD symptoms in former and current smokers, clinical trials show